IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease

Kirk A. Staschke(Indiana University School of Medicine), Songqing Na(Eli Lilly (United States))

The Journal of Immunology

June 19, 2009

10.4049/jimmunol.0802361

Cited by 54

Related Papers

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

|Clinical Cancer Research|2023|27

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer

|Science Signaling|2024|9

GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis

|bioRxiv (Cold Spring Harbor Laboratory)|2022|4

Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models

|Cancer Research|2023|3

Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML

|Blood|2023|3